Relevant bibliographies by topics / Nemalobuněčný plicní karcinom

Contents

  1. Journal articles
  2. Dissertations / Theses

Academic literature on the topic 'Nemalobuněčný plicní karcinom'

Author: Grafiati
Published: 4 June 2021
Last updated: 6 February 2022

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Nemalobuněčný plicní karcinom.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "Nemalobuněčný plicní karcinom"

1

Skřičková, Jana, Bohdan Kadlec, and Ondřej Venclíček. "Non-small cell lung cancer." Vnitřní lékařství 63, no. 11 (November 1, 2017): 861–74. http://dx.doi.org/10.36290/vnl.2017.159.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Venclíček, Ondřej. "Treatment of patients with non-small cell lung cancer with ALK rearrangement." Onkologie 12, no. 4 (September 1, 2018): 182–84. http://dx.doi.org/10.36290/xon.2018.033.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Stejskal, Jan. "Serious complications in a patient with generalized non-small cell lung cancer treated with pembrolizumab." Onkologie 14, Suppl.A (June 2, 2020): 17–20. http://dx.doi.org/10.36290/xon.2020.030.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Skřičková, Jana, Kateřina Fröhlich, Matyáš Kuhn, Zbyněk Bortlíček, Karel Hejduk, Miloš Pešek, Vítězslav Kolek, et al. "Continuation maintenance therapy with pemetrexed in patients with non-small-cell lung cancer in the Czech Republic." Onkologie 10, no. 1 (March 1, 2016): 31–36. http://dx.doi.org/10.36290/xon.2016.008.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Koubková, Leona. "Case report of a patient with metastatic non-small cell lung cancer with positive ALK gene rearrangement treated in the first line with alectinib." Onkologie 14, Suppl.D (June 2, 2020): 71–74. http://dx.doi.org/10.36290/xon.2020.042.

Full text
APA, Harvard, Vancouver, ISO, and other styles

Dissertations / Theses on the topic "Nemalobuněčný plicní karcinom"

1

Kulda, Vlastimil. "Regulace genové exprese v nádorové tkáni." Doctoral thesis, 2018. http://www.nusl.cz/ntk/nusl-388199.

Full text
Abstract:
Deregulation of gene expression caused by genetic or epigenetic changes plays an important role in pathogenesis of cancer. The thesis is a commented collection of ten publications dealing with the molecular biology of tumours. The author has significantly contributed to all of them. All the articles contained in the thesis are linked to the topic of assessment of molecules involved in gene expression regulation (microRNAs) or DNA alterations that affect gene expression (promoter methylation, presence of a fusion gene). MicroRNAs are short single-stranded RNA molecules involved in posttranscriptional regulation of gene expression by triggering mRNA degradation or inhibiting translation. It is a basic mechanism with an impact on all cellular processes including the pathogenesis of various diseases. MicroRNAs can either act as oncogenes by decreasing the expression of tumour-suppressor genes or as tumour-suppressor genes by decreasing the expression of oncogenes. However, the network of microRNA - RNA interactions is much more complex. Our published results that are part of this thesis are focused on colorectal carcinoma (CRC), prostate cancer, head and neck squamous cell carcinoma (HNSCC), gastric cancer and non-small cell lung cancer (NSCLC). In patients with CRC, we demonstrated the prognostic...
APA, Harvard, Vancouver, ISO, and other styles
2

Vojtíšek, Radovan. "Vliv PET/CT vyšetření při plánování radioterapie nemalobuněčných plicních karcinomů." Doctoral thesis, 2015. http://www.nusl.cz/ntk/nusl-350104.

Full text
Abstract:
The impact of PET/CT scanning in the radiotherapy planning of non-small cell lung cancer Background: In the current practice of radiotherapy planning and target volume determination in patients suffering from the non-small cell lung cancer (NSCLC), a contrast-enhanced CT is standard procedure. Contemporary studies have proven that PET/CT examination attains higher sensitivity and specificity in the diagnosis of lung cancer and also leads to higher accuracy in the process of target-volume delineation in NSCLC. Aim: To compare radiotherapy plans made according to CT and PET/CT examinations in the same patient and to investigate the impact of changes in target volume sizes on tumor control probability (TCP) and normal tissue complication probability (NTCP) and the impact of combined PET/CT examination on the staging of the disease and treatment strategy. Materials and Methods: Between October 2008 and November 2013, 42 patients suffering from pathologically proven inoperable locally advanced NSCLC that were referred to radical radiotherapy were involved in our study. They all underwent planning PET/CT examination. I carried out two separate delineations of target volumes and two radiotherapy plans, both with their own dose-volume histograms (DVH). I compared the following parameters of radiotherapy...
APA, Harvard, Vancouver, ISO, and other styles
3

Fikrová, Petra. "Hodnocení poškození a reparace DNA u pacientů s nemalobuněčným plicním karcinomem vzhledem k farmakoterapii deriváty platiny." Doctoral thesis, 2013. http://www.nusl.cz/ntk/nusl-328222.

Full text
Abstract:
Charles University in Prague Faculty of Pharmacy in Hradec Kralove Department of Biological and Medical Sciences Candidate: Mgr. Petra Fikrová Supervisor: Doc. PharmDr. Miloslav Hronek, Ph.D. Consultant: Prof. RNDr. Rudolf Štětina, CSc. Title of doctoral thesis: Evaluation of DNA damage and repair in patients with non-small cell lung cancer due to drug therapy with platinum derivatives Lung cancer is the most common worldwide cause of cancer-related death. This type of cancer is divided into two subtypes, the small cell and non-small cell lung cancer. Platinum- based chemotherapy is the mainstay of treatment of advanced stages non-small cell lung cancer, to that is this work focused on. The aim of this study was to investigate whether it is possible to use the comet assay method for monitoring the progress of treatment in these patients, and if it is possible to predict a patient's response to treatment or patient's survival. Standard version or modifications of comet assay were used for the measurement of DNA damage or oxidative DNA damage and we also validated a modification of comet assay for measuring DNA crosslinks. This evaluation was carried out either in vitro in HeLa cells and in peripheral blood lymphocytes from healthy donors from Transfusion department of University Hospital in Hradec...
APA, Harvard, Vancouver, ISO, and other styles
4

Pražáková, Markéta. "Klinický význam biomarkerů pro posouzení agresivity a prognozu nemalobuněčného karcinomu plic." Doctoral thesis, 2011. http://www.nusl.cz/ntk/nusl-358410.

Full text
Abstract:
Aim: The aim of this thesis was to measure a large spectrum of biomarkers in serum or plasma of patients with operable stage of NSCLC and to evaluate and compare the clinical utility of these biomarkers in the three most important clinical applications for NSCLC: diagnosis, prognosis and postsurgery follow up care. Patients and methods: Total of 22 biomarkers with the most promising profiles were monitored: 8 standard tumor markers (cytokeratines Cyfra 21-1, TPA, TPS, and MonoTotal, CEA, SCC, TK, Chromogranin A) and 14 potential useful biomarkers including pro-inflammatory cytokines IL-6, IL-8, MCP-1, pro-angiogenic cytokine VEGF, matrix metaloproteinases MMP-1, MMP-2, MMP-7, MMP-9 and their inhibitors TIMP-1 and TIMP-2, adhesion molecules ICAM-1, VCAM-1, growth factor IGF-1, and PAI-1 stimulating tumor growth and angiogenesis. With a view of evaluating the clinical relevance of these markers for NSCLC we measured serum or plasma levels of these 22 markers in group of 93 patients with NSCLC undergoing radical surgery and in group of 20 patients with benign lung disease. For biomarker measurement were used conventional immunoanalytic routine methods (IRMA, REA, CLIA, MEIA, TRACE, ELISA) and multiplex immunoanalytic method. Results: Cyfra 21-1, MonoTotal, TPA, TPS, CEA, SCC, Chromogranin A, TIMP-1, MMP-1,...
APA, Harvard, Vancouver, ISO, and other styles
5

Rozkoš, Tomáš. "Stanovení optimálního vyšetřovacího algoritmu pro efektivní vyhledávání nemalobuněčných karcinomů plic s přestavbou genu ALK." Doctoral thesis, 2017. http://www.nusl.cz/ntk/nusl-308952.

Full text
Abstract:
(Identification of optimal algorithm for effective diagnostics of non-small cell lung carcinoma with ALK gene rearrangement - implementation of the method and practical experience with routine diagnostics) INTRODUCTION: Smaller subgroup of non-small cell lung carcinoma (NSCLC) is represented by tumours with carcinogenesis iniciated by fusion of ALK gene with another partner (usually EML4). Patients with ALK gene rearrangement treated with ALK inhibitors have significantly prolonged survival. Since ALK gene rearrangement is described according to the current WHO classification in 4-5% of NSCLC, it is necessary to find the optimal way of identifying patients eligible for this targeted therapy in routine diagnostic practice. AIM: In the retrospective part of the study a) to find an immunohistochemical (IHC) detection procedure of ALK protein with specificity and sensitivity high enough to use this antibody as screening method for selecting NSCLC cases for fluorescence in situ hybridization (FISH) testing of ALK gene rearrangement and b) to determine diagnostic yield of "small" biopsies, i.e. endobronchial, transbronchial and transthoracic biopsies and cytoblocks, for ALK gene rearrangement testing. In the prospective part of the study a) verification of the selected IHC method of ALK protein detection...
APA, Harvard, Vancouver, ISO, and other styles
6

Fiala, Ondřej. "Možnosti predikce efektu léčby EGFR tyrozinkinázovými inhibitory u pacientů s pokročilým nemalobuněčným karcinomem plic." Doctoral thesis, 2014. http://www.nusl.cz/ntk/nusl-342344.

Full text
Abstract:
Introduction: Targeted therapy with low molecular-weight tyrosine kinase inhibitors (TKI) directed at inhibition of epidermal growth factor receptor (EGFR) is a novel effective option for systemic treatment of locally-advanced or metastatic non-small cell lung cancer (NSCLC). Finding biomarkers that predict the efficacy of targeted treatment may increase the treatment efficacy and also prolong survival of patients. Aims: To assess the frequency of activating EGFR mutations and KRAS mutations in our patients and their role for prediction of EGFR-TKI treatment efficacy. To compare the efficacy and safety of EGFR-TKI and chemotherapy in the first-line treatment of patients harboring activating EGFR mutations. Methods: 613 patients with cytologically or histologically confirmed NSCLC were tested for activating EGFR mutation, of which 448 patients were also tested for KRAS mutation. First-line therapy was evaluated in 54 patients harboring activating EGFR mutations. Mutations were detected using denaturing capillary electrophoresis, and verified by direct DNA sequencing. Survival of patients was assessed using the methodology of Kaplan-Meier, the comparison was calculated using log-rank test. Results: Activating EGFR mutations were detected in 73 (11.9%) patients, more frequently in patients with...
APA, Harvard, Vancouver, ISO, and other styles
7

Kobosilová, Linda. "Exprese markerů imunogenní buněčné smrti na buňkách karcinomu plic." Master's thesis, 2014. http://www.nusl.cz/ntk/nusl-332417.

Full text
Abstract:
Immunogenic cell death (ICD) is characterized by presence of specific molecules including surface exposed calreticulin (CRT) and the heat shock proteins HSP70 and HSP90. Release of ATP and high- mobility group box protein 1 (HMGB1) belongs to other typical characteristics. For induction of ICD in lung cancer cells high-hydrostatic pressure (HHP) was used. Treatment by HHP induces expression of immunogenic markers CRT, HSP70 and HSP90 on the cell surface. HHP also induces secretion of ATP to the extracellular milieu. Dendritic cells (DC) pulsed with HHP-treated tumor cells showed fenotypic maturation characterized by upregulation of maturation molecule CD83, costimulation molecules CD80 and CD86, chemokine receptor CCR7 and MHC class II molecule HLA-DR. Pulsed DCs have also higher rate of phagocytosis of HHP-treated tumor cells and they induce lower numbers of regulatory T cells compared to immature DCs. Moreover, activation of caspases (-8, -9, -3) and other proteins (phosphorylation of eIF2α) which are crucial in ER-stress mediated apoptotic pathway, was observed after HHP treatment. Using wide range of methods it was confirmed that HHP treatment is able to induce ICD in lung cancer cell lines, fenotypic and functional characteristics were described and the decreased induction of regulatory T-lymphocytes...
APA, Harvard, Vancouver, ISO, and other styles
We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!

To the bibliography